HS-20094
RISE-1
Regeneron · Phase 3 · Not yet recruiting · Enrollment 3000
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Olatorepatide-Dose 1 | n/r | n/r | n/r | n/r |
| Olatorepatide-Dose 2 | n/r | n/r | n/r | n/r |
| Olatorepatide-Dose 3 | n/r | n/r | n/r | n/r |
| Placebo-Dose 1 | n/r | n/r | n/r | n/r |
| Placebo-Dose 2 | n/r | n/r | n/r | n/r |
Not shown
- Olatorepatide-Dose 1: endpoint not reported
- Olatorepatide-Dose 2: endpoint not reported
- Olatorepatide-Dose 3: endpoint not reported
- Placebo-Dose 1: endpoint not reported
- Placebo-Dose 2: endpoint not reported